COMPANY PROFILE

immuneel

Explore full profile

Translating research discoveries into transformative therapies for individuals with allergies

Bengaluru, IndiaFounded 2018Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2026

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About immuneel

Immuneel Therapeutics Private Limited is at the forefront of bringing advanced cancer treatments to India, focusing on cell, gene, and immunotherapy. These cutting-edge therapies offer new hope to millions of cancer patients. The company collaborates with leading global experts to develop and deliver high-quality cell therapies at an affordable cost. Immuneel serves cancer patients in India and aims to expand its reach beyond. The business operates in the healthcare and biotechnology market, primarily targeting oncology. Its business model involves research and development, clinical trials, and partnerships with healthcare providers to bring innovative therapies to market. Revenue is generated through the commercialization of these therapies, partnerships, and potentially licensing agreements.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Bengaluru, India
Employees: 112
Open positions: 3
Dealroom signal: 55.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning immuneel.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jun 2026	$10M	$75M	F-Prime · Eight Roads Ventures · Kiran Mazumdar-Shaw · Singularity AMC	↗
SERIES A✓Equity / VC	Jul 2024	$12M	$75M	Taiba Healthcare	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

immuneel website traffic

Latest recorded traffic for immuneel is 14K monthly website visits, up 508.7% over the last three months. immuneel's team grew 6.7% over the past year.

Latest monthly visits14K 3-month web change+508.7% 1-year team growth+6.7%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SPSpireaAdvanced antibody-drug conjugate technology for cancer therapeutics	Harrogate, United Kingdom	Operational	8	$3.8M	$13M
CECellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer	Óbidos, Portugal	Acquired
VTValo TherapeuticsAn immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines	Helsinki, Finland	Operational
OTOna TherapeuticsSpecializes in the discovery and development of therapeutic biologics targeting the lipid metabolism in order to treat advanced cancer	Barcelona, Spain	Operational
DADJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases	Oxford, United Kingdom	Acquired
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
ABAC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients	Ecublens, Switzerland	Operational